不同抗胆碱能量表的使用及其与HIV感染者抗胆碱能症状负担的相关性
该横断面研究在721名HIV感染者中计算了三种抗胆碱能量表(ABS、ARS、ADS)评分,并记录过去3个月抗胆碱能症状/体征。22.7%的参与者使用至少一种抗胆碱能药物,其中28.6%出现至少一种抗胆碱能症状/体征。ABS和ADS的筛查准确性最佳(AUROC分别为0.85和0.84),但在通用人群截断值下三种量表敏感性均很低。
要点
- 22.7%的HIV感染者使用至少一种抗胆碱能药物,其中28.6%出现抗胆碱能症状/体征。
- 双药方案与抗胆碱能症状/体征风险降低相关(aOR=0.12,P=0.002),抗胆碱能药物数量增加与风险升高相关(aOR=12.91,P<0.001)。
- ABS和ADS的AUROC分别为0.85和0.84,但通用人群截断值下敏感性仅34.0%、46.8%和46.8%。
核心结论
- 近四分之一HIV感染者暴露于至少一种抗胆碱能药物,其中超过四分之一出现抗胆碱能症状/体征。
- 多种药物(抗逆转录病毒药物数量及具有抗胆碱能特性的合并用药数量)及部分合并症影响抗胆碱能症状/体征风险。
- HIV感染者的抗胆碱能风险筛查应优先选择ABS或ADS,并采用低于通用人群建议的截断值。
研究设计与样本
- 横断面研究,纳入721名成年HIV感染者,计算ABS、ARS和ADS评分并记录过去3个月抗胆碱能症状/体征。
- 高抗胆碱能风险定义为ABS评分≥2分,ARS或ADS评分≥3分。
主要发现
- 721名参与者中72.0%为男性,中位年龄53岁,164人(22.7%)使用至少一种抗胆碱能药物。
- 使用至少一种抗胆碱能药物的参与者中,28.6%经历至少一种抗胆碱能症状/体征。
- 仅ARS与ADS之间风险分类一致性为中等(k=0.6)。
- 双药方案与抗胆碱能症状/体征风险降低相关(aOR=0.12,对比三药方案,P=0.002),抗胆碱能药物数量增加与风险升高相关(aOR=12.91,P<0.001)。
- 抑郁和COPD在未校正抗胆碱能药物数量的分析中与抗胆碱能症状/体征风险升高相关。
关键数值与推荐
- ABS和ADS的AUROC分别为0.85(0.78-0.92)和0.84(0.75-0.92),两者P<0.001。
- 在通用人群截断值下,三种量表的敏感性分别为34.0%、46.8%和46.8%。
临床怎么用
- 作者认为HIV感染者的抗胆碱能风险敏感筛查应优先选择ABS或ADS,并采用低于通用人群建议的截断值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: How to detect the clinical impact of anticholinergic (AC) burden in people with HIV (PWH) remains poorly investigated. We cross-sectionally described the prevalence and type of AC signs/symptoms and the screening accuracy of three AC scales in detecting their presence in a modern cohort of PWH. METHODS: We calculated AC Burden Scale (ABS), AC Risk Score (ARS) and AC Drug Score (ADS) in 721 adult PWH and recorded the presence of AC signs/symptoms over the previous 3 months. High AC risk was defined by ABS score ≥2, and ARS or ADS score ≥3. Comparisons among the scale were based on Cohen's inter-rater agreement, and their screening accuracy was assessed by receiver operating characteristics (ROC) curves and performance measures. RESULTS: We enrolled 721 PWH, of whom 72.0% of participants were male; the median age was 53 years, and 164 participants (22.7%) were on at least one AC drug. Among these, 28.6% experienced at least one AC sign/symptom. Agreement in AC risk classification was substantial only between ARS and ADS (k = 0.6). Lower and higher risk of AC signs/symptoms was associated with dual regimens [adjusted OR (aOR) = 0.12 versus three-drug regimens, P = 0.002] and increasing number of AC drugs (aOR = 12.91, P < 0.001). Depression and COPD were also associated with higher risk of AC signs/symptoms in analysis unadjusted for number of AC drugs. ABS and ADS showed the best area under the ROC curve (AUROC) of 0.85 (0.78-0.92) and 0.84 (0.75-0.92; P < 0.001 for both). However, at the cut-off used for the general population, the sensitivity of all three scales was very low (34.0%, 46.8% and 46.8%). CONCLUSIONS: Up to one-fourth of participants in our cohort were exposed to at least one AC drug, and among them AC signs/symptoms affected more than one-fourth. Both polypharmacy (as number of antiretrovirals and of co-medications with AC properties) and to a lesser extent specific comorbidities shaped the risk of developing AC signs/symptoms. Sensitive screenings for AC risk in PWH should prefer ABS or ADS based on lower cut-offs than those suggested for the general population.
引用
- Mazzitelli M, Trunfio M, Coin A, et al. Use of different anticholinergic scales and their correlation with anticholinergic symptom burden in a cohort of people living with HIV. J Antimicrob Chemother. 2024. PMID: 37965917. doi:10.1093/jac/dkad348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。